New York, July 9 (SharewellNewswire.com) – Valuing emerging biotech or healthcare companies exclusively based on past performance is like valuing an MBA prospect by little league performance. From developing a blockbuster product (good) to product recalls (bad), revenue can take off in any direction for healthcare. At the same time, my research has shown that